Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Chinese Hamster Ovary (CHO) cells have played a pivotal role in the production of biopharmaceutical proteins since their ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...

At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...